Description
Anti-GD2 Antibody, Non-Fucosylated (BioBet-019ZP) is a mouse monoclonal IgG1 antibody against GD2. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced GD2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GD2
Full Name
Disialoganglioside GD2
Alternative Names
dinutuximab;Unituxin;Ch14.18;APN311;Disialoganglioside GD2;Ganglioside G2;GD2
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-019ZP
Description
Dinutuximab is a monoclonal antibody composed of mouse and human components used as a second-line treatment for children with high-risk neuroblastoma. It targets the glycolipid GD2 expressed on neuroblastoma cells and normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. Dinutuximab obtained marketing authorization in the U.S. and Europe in 2015.
Antibody Indication
High Risk Neuroblastoma
Melanoma
High Risk Neuroblastoma
Melanoma
